Skip to content
Triangle logo TriangleGet started
← Study library

NCT02013180 · REGISTRY CONDITION SEARCH

Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
Not reported
Status at capture
COMPLETED
Registry last update
2019-04-16

Although Prostate Specific Antigen (PSA) is a useful marker for early detection of the prostate cancer, its specivity is not sufficient. Several PSA variations were defined in order to increase the specivity of the test, but they aren't much more effective than the PSA alone for detection of disease. In older studies reported that, serum and prostatic tissue zinc levels decreased in prostat cancer disease. In our study we aimed to establish the utility of serum zinc, PSA, free PSA/PSA (fPSA/tPSA), zinc/PSA, levels for early detection of the prostate cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: Patients with LUTS and elevated serum PSA levels and/or suspicious rectal examination Exclusion Criteria: usage of zinc included drugs, older prostatic operations, older prostatic radiotherapy, older prostatic biopsies, chronic rectal diseases (anal fissure, hemorrhoid, etc..), PIN(prostatic intraepithelial neoplasia) and ASAP(atypical small acinar proliferation) in pathologic evaluation.
healthy Volunteers
false
sampling Method
NON_PROBABILITY_SAMPLE
sex
MALE
std Ages
  1. CHILD
  2. ADULT
  3. OLDER_ADULT
study Population
patient with LUTS(lower urinary tract symptomps) and elevated serum PSA levels/suspicious rectal examination who undergone transrectal ultrasonography guided prostate biopsy
Treatment arms and interventions
arm Groups
  1. description
    prostate adenocarcinoma in pathologic evaluation
    label
    prostate cancer
  2. description
    benign prostatic diseases in pathologic evaluation
    label
    control
Study design
observational Model
CASE_CONTROL
time Perspective
PROSPECTIVE
Enrollment
count
480
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Does the zinc/PSA ratio show statistically signifacant difference in patients with prostate cancer?
    measure
    Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases
    time Frame
    measurement of serum zinc and PSA levels are performed prior to transrectal prostat biopsy; pathologic evaluation of biopsy specimens are performed within 2-3 weeks
Full study description
brief Summary
Although Prostate Specific Antigen (PSA) is a useful marker for early detection of the prostate cancer, its specivity is not sufficient. Several PSA variations were defined in order to increase the specivity of the test, but they aren't much more effective than the PSA alone for detection of disease. In older studies reported that, serum and prostatic tissue zinc levels decreased in prostat cancer disease. In our study we aimed to establish the utility of serum zinc, PSA, free PSA/PSA (fPSA/tPSA), zinc/PSA, levels for early detection of the prostate cancer.
Source references
references
  1. citation
    Temiz MZ, Cakir OO, Aykan S, Kucuk SH, Tiryakioglu NO, Bilek G, Tunali NE, Kandirali E, Semercioz A. The use of serum zinc to prostate-specific antigen ratio as a biomarker in the prediction of prostate biopsy outcomes. Biomark Med. 2019 Feb;13(2):59-68. doi: 10.2217/bmm-2018-0260. Epub 2019 Jan 23.
    pmid
    30672309
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-661cb4aeddb008511936
      requested nct id
      NCT02013180
      primary nct id
      NCT02013180
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
      payload sha256
      79e7c5e5637e410931847808c1a11da7f86f1801271b2f617b647f01c46dfb14
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-661cb4aeddb008511936
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02013180
      occurrences
      1. context exact
        NCT02013180
        end
        11
        exact text
        NCT02013180
        start
        0
      offset unit
      unicode_code_points
      query cond
      Salivary Gland Cancer
      query disease state id
      ds-salivary-gland-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-salivary-gland-cancer-000.json
      source file sha256
      38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
      source json pointer
      /studies/40/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      4533cd2ee37478cb23c79c348b30fca7c152c278bcc7aea78da3dcb168538e1f

    Preserved source evidence · Not medical advice